Alimta

Updated: New York: Oct 20 09:00London: Oct 20 14:00Tokyo: Oct 20 22:00 US AUBZFPGRHKIMJPLNSMIND : Regions Top Worldwide Regions Asia Australia & New Zealand Canada Europe Germany Japan Latin America U.K.

U.S.

Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets U.S.

E-Mail This Story Printer-Friendly Format Pfizer's Earnings Plunge 52 Percent on Lower Sales of Celebrex Painkiller Ford Posts Loss of $284 Million on Lower SUV Sales, Its First Since 2003 Eli Lilly Net Income Rises on Sales of Antidepressants, Cancer Treatments Lilly's 3rd-Qtr Profit Rises 5.2% on New Drugs (Update2) Oct.

20 (Bloomberg) - Eli Lilly & Co.

said third-quarter profit rose 5.2 percent as it controlled costs and sold more of its newer medicines, such as the Cymbalta antidepressant and Net income for Lilly rose to $794.4 million, or 73 cents a share, from $755 million, or 69 cents, a year earlier, Indianapolis-based Lilly said in a statement.

Sales rose 10 percent to $3.6 billion, while Lilly's cost to produce these medicines rose 4 percent to $845.7 million.

Lilly is planning on saving $150 million this year through costs cuts, including job reductions announced in 2004, according to the company Web site.

U.S.

sales of its Strattera attention-deficit-disorder drug and the Zyprexa schizophrenia treatment, Lilly's biggest product, fell because of concerns about side aff...

Read more...